Surgical Techniques in Diabetes Mellitus-II and Obesity. Metabolic Surgery Study (MSS)
- Conditions
- Diabetes MellitusObesity
- Interventions
- Procedure: Modified gastric bypass.Procedure: Gastric bypassProcedure: Slevee Gastrectomy
- Registration Number
- NCT02310555
- Lead Sponsor
- Hospital Universitario Virgen de la Arrixaca
- Brief Summary
The aim of this study is to compare clinical and laboratory findings of three surgical techniques in metabolic surgery in patients with type II diabetes mellitus and obesity (BMI\> 30).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 90
- BMI 30-40
- Diabetes Mellitus type II less than 10 years of evolution.
- Anti-GAD, anti-pancreatic islets negative antibodies.
- C peptide normally between 0.9 and 4.
- Glycosylated hemoglobin greater than 6.5%.
- Less than 5 years of use insulin.
- Cirrosis hepática.
- coagulopathies.
- Type 1 diabetes.
- HIV positive.
- Stomach or small intestine previous surgeries .
- Diseases of the exocrine pancreas: pancreatitis, pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis.
- Endocrinopathies: acromegaly, glucagonoma, Cushing's syndrome, pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma.
- Genetic syndromes with diabetes.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Modified gastric bypass. Modified gastric bypass. Modified gastric bypass. Resection body and fundus gastric Gastric bypass Gastric bypass classic Gastric bypass Slevee Gastrectomy Slevee Gastrectomy Slevee Gastrectomy
- Primary Outcome Measures
Name Time Method Remission diabetes mellitus type II Durign two years 1. Partial remission: Not diagnostic of DM HbA1c (\<6.5%); Basal glucose 100-125 mg / dl (5.6-6.9 mmol / l); Absence of drug treatment; At least one year.
2. Complete remission: Normal HbA1c (\<6%); basal glucose \<100 mg / dl (\<5.6 mmol / l); Absence of drug treatment; At least one year.
3. Prolonged remission: At least 5 years of remission.
4. Improvement: HbA1c \<7% with pharmacological treatment.
- Secondary Outcome Measures
Name Time Method Adverse effects in the short term During three months since surgery We'll measure the number of patients with postoperative complications and the the degree of severity of Clavien- Dindo Classification
Adverse effects in the long term Since third month after surgery untiil two years We'll measure the number of patients with postoperative complications and the the degree of severity of Clavien- Dindo Classification
Weight loss During two years
Trial Locations
- Locations (1)
Hospital Clínico Universitario Virgen de la Arrixaca
🇪🇸El Palmar., Murcia, Spain